Harrow Health Inc (NASDAQ:HROW) — Market Cap & Net Worth
Market Cap & Net Worth: Harrow Health Inc (HROW)
Harrow Health Inc (NASDAQ:HROW) has a market capitalization of $1.51 Billion ($1.51 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7342 globally and #2107 in its home market, demonstrating a 5.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Harrow Health Inc's stock price $40.90 by its total outstanding shares 37037453 (37.04 Million). Analyse HROW cash generation efficiency to see how efficiently the company converts income to cash.
Harrow Health Inc Market Cap History: 2015 to 2026
Harrow Health Inc's market capitalization history from 2015 to 2026. Data shows growth from $256.67 Million to $1.51 Billion (18.64% CAGR).
Index Memberships
Harrow Health Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.06% | #194 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #784 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.09% | #124 of 263 |
Weight: Harrow Health Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Harrow Health Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Harrow Health Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.23x
Harrow Health Inc's market cap is 6.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $256.67 Million | $9.72 Million | -$15.90 Million | 26.42x | N/A |
| 2016 | $92.59 Million | $19.94 Million | -$19.09 Million | 4.64x | N/A |
| 2017 | $62.96 Million | $26.77 Million | -$11.98 Million | 2.35x | N/A |
| 2018 | $210.74 Million | $41.37 Million | $14.62 Million | 5.09x | 14.41x |
| 2019 | $288.15 Million | $51.16 Million | $168.00K | 5.63x | 1715.19x |
| 2020 | $254.08 Million | $48.87 Million | -$3.36 Million | 5.20x | N/A |
| 2021 | $320.00 Million | $72.48 Million | -$18.01 Million | 4.42x | N/A |
| 2022 | $546.67 Million | $88.59 Million | -$14.09 Million | 6.17x | N/A |
| 2023 | $414.82 Million | $130.19 Million | -$24.41 Million | 3.19x | N/A |
| 2024 | $1.24 Billion | $199.61 Million | -$17.48 Million | 6.23x | N/A |
Competitor Companies of HROW by Market Capitalization
Companies near Harrow Health Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Harrow Health Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Harrow Health Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Harrow Health Inc's market cap moved from $256.67 Million to $ 1.51 Billion, with a yearly change of 18.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.51 Billion | -16.53% |
| 2025 | $1.81 Billion | +46.05% |
| 2024 | $1.24 Billion | +199.55% |
| 2023 | $414.82 Million | -24.12% |
| 2022 | $546.67 Million | +70.83% |
| 2021 | $320.00 Million | +25.95% |
| 2020 | $254.08 Million | -11.83% |
| 2019 | $288.15 Million | +36.73% |
| 2018 | $210.74 Million | +234.71% |
| 2017 | $62.96 Million | -32.00% |
| 2016 | $92.59 Million | -63.92% |
| 2015 | $256.67 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Harrow Health Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.51 Billion USD |
| MoneyControl | $1.51 Billion USD |
| MarketWatch | $1.51 Billion USD |
| marketcap.company | $1.51 Billion USD |
| Reuters | $1.51 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, … Read more